Maiden interim results are slightly ahead of our expectations with a better performance on cash preservation. This should be taken positively in light of the strong strategic progress in the period. The validation study of Clarava and Tuteva is on track to complete by year-end 2021 and, pending the outcome of the data in Q1 2022, be commercially launched in 2022. We have made no headline forecast changes, but the Company is well-placed to execute against our FY’21E estimates and is fully funded ....
13 Sep 2021
Pleasing Maiden interims; validation study on track
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Pleasing Maiden interims; validation study on track
Verici Dx Plc (VRCI:LON) | 7.8 0 0.0% | Mkt Cap: 18.8m
- Published:
13 Sep 2021 -
Author:
Edward Thomason -
Pages:
3
Maiden interim results are slightly ahead of our expectations with a better performance on cash preservation. This should be taken positively in light of the strong strategic progress in the period. The validation study of Clarava and Tuteva is on track to complete by year-end 2021 and, pending the outcome of the data in Q1 2022, be commercially launched in 2022. We have made no headline forecast changes, but the Company is well-placed to execute against our FY’21E estimates and is fully funded ....